





# PHARMACEUTICAL 2018

Loxo Oncology Inc.  
Rank 101 of 349

The relative strengths and weaknesses of Loxo Oncology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Loxo Oncology Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 169% points. The greatest weakness of Loxo Oncology Inc. is the variable Revenues, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is -32%, being 246% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	781,807
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	221,570
Liabilities, Non-Current	0
Other Assets	723
Other Compr. Net Income	-551
Other Expenses	0
Other Liabilities	183,662
Other Net Income	24,820
Property and Equipment	912
Research and Development	140,039
Revenues	0
Selling, General and Administrative Expense	33,657

Output Variable	Value in 1000 USD
Assets	783,442
Liabilities	405,232
Expenses	173,696
Stockholders Equity	378,210
Net Income	-148,876
Comprehensive Net Income	-149,152
Economic Capital Ratio	-32%

